{"doi":"10.1111/bpa.12048","title":"Dysembryoplastic Neuroepithelial Tumors Share with Pleomorphic Xanthoastrocytomas and Gangliogliomas <scp>BRAF<sup>V600E</sup></scp> Mutation and Expression","abstract":"<jats:title>Abstract</jats:title><jats:p>Pediatric cortical glioneuronal benign tumors mainly include gangliogliomas (<jats:styled-content style=\"fixed-case\">GG</jats:styled-content>) [differential diagnoses pilocytic astrocytomas (<jats:styled-content style=\"fixed-case\">PA</jats:styled-content>) and pleomorphic xanthoastrocytomas (<jats:styled-content style=\"fixed-case\">PXA</jats:styled-content>)] and dysembryoplastic neuroepithelial tumor (<jats:styled-content style=\"fixed-case\">DNT</jats:styled-content>). <jats:styled-content style=\"fixed-case\">DNT</jats:styled-content> include the specific form and the controversial non‐specific form that lack the specific glioneuronal element. Our aims were to search for <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<jats:sup>V600E</jats:sup></jats:styled-content></jats:italic> mutation and <jats:styled-content style=\"fixed-case\">CD</jats:styled-content>34 expression in <jats:styled-content style=\"fixed-case\">DNT</jats:styled-content>, <jats:styled-content style=\"fixed-case\">PXA</jats:styled-content>, <jats:styled-content style=\"fixed-case\">GG</jats:styled-content> and <jats:styled-content style=\"fixed-case\">PA</jats:styled-content> to correlate <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<jats:sup>V600E</jats:sup></jats:styled-content></jats:italic> mutation with <jats:styled-content style=\"fixed-case\">BRAF<jats:sup>V600E</jats:sup></jats:styled-content> expression and to evaluate their diagnostic and prognostic values. Ninety‐six children were included. <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<jats:sup>V600E</jats:sup></jats:styled-content></jats:italic> mutation was studied by sequencing and immunohistochemistry; <jats:styled-content style=\"fixed-case\">CD</jats:styled-content>34 expression was analyzed by immunohistochemistry. <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<jats:sup>V600E</jats:sup></jats:styled-content></jats:italic> mutation was detected in <jats:styled-content style=\"fixed-case\">PXA</jats:styled-content> (60%), <jats:styled-content style=\"fixed-case\">GG</jats:styled-content> (38.7%), <jats:styled-content style=\"fixed-case\">DNT</jats:styled-content> (30%, including 3/11 specific and 3/9 non‐specific forms) and <jats:styled-content style=\"fixed-case\">PA</jats:styled-content> (12.5%). <jats:styled-content style=\"fixed-case\">BRAF<jats:sup>V600E</jats:sup></jats:styled-content> expression was recorded in <jats:styled-content style=\"fixed-case\">PXA</jats:styled-content> (60%), <jats:styled-content style=\"fixed-case\">GG</jats:styled-content> (45.2%) and <jats:styled-content style=\"fixed-case\">DNT</jats:styled-content> (30%). <jats:styled-content style=\"fixed-case\">CD34</jats:styled-content> expression was recorded in <jats:styled-content style=\"fixed-case\">PXA</jats:styled-content> (60%), <jats:styled-content style=\"fixed-case\">GG</jats:styled-content> (58.1%), <jats:styled-content style=\"fixed-case\">DNT</jats:styled-content> (25%) and <jats:styled-content style=\"fixed-case\">PA</jats:styled-content> (12.5%). Neither <jats:styled-content style=\"fixed-case\">CD</jats:styled-content>34 expression nor <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<jats:sup>V600E</jats:sup></jats:styled-content></jats:italic> status was predictive of prognosis, except for <jats:styled-content style=\"fixed-case\">PA</jats:styled-content> tumors where <jats:styled-content style=\"fixed-case\">CD</jats:styled-content>34 expression was associated with a shorter overall survival. In conclusion, <jats:styled-content style=\"fixed-case\">DNT</jats:styled-content> shared with <jats:styled-content style=\"fixed-case\">PXA</jats:styled-content> and <jats:styled-content style=\"fixed-case\">GG</jats:styled-content>, <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<jats:sup>V600E</jats:sup></jats:styled-content></jats:italic> mutation and/or <jats:styled-content style=\"fixed-case\">CD</jats:styled-content>34 expression, which represent molecular markers for these tumors, and we recommend searching for <jats:styled-content style=\"fixed-case\">CD</jats:styled-content>34 expression and <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<jats:sup>V600E</jats:sup></jats:styled-content></jats:italic> mutation in all <jats:styled-content style=\"fixed-case\">DNT</jats:styled-content>, especially the non‐specific forms.</jats:p>","journal":"Brain Pathology","year":2013,"id":640233,"datarank":0.7814229229262133,"base_score":5.209486152841421,"endowment":5.209486152841421,"self_citation_contribution":0.7814229229262133,"citation_network_contribution":0.0,"self_endowment_contribution":0.7814229229262133,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":182,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1663866,"name":"Laetitia Padovani","orcid":null,"position":1,"is_corresponding":false},{"id":1558505,"name":"Didier Scavarda","orcid":"0000-0001-9344-8071","position":2,"is_corresponding":false},{"id":1570574,"name":"Fabien Forest","orcid":"0000-0001-7582-3923","position":3,"is_corresponding":false},{"id":1663867,"name":"Isabelle Nanni‐Metellus","orcid":null,"position":4,"is_corresponding":false},{"id":1606255,"name":"Anderson Loundou","orcid":null,"position":5,"is_corresponding":false},{"id":1663868,"name":"Sandy Mercurio","orcid":null,"position":6,"is_corresponding":false},{"id":1663869,"name":"Frédéric Fina","orcid":null,"position":7,"is_corresponding":false},{"id":1663870,"name":"Gabriel Lena","orcid":null,"position":8,"is_corresponding":false},{"id":1663871,"name":"Carole Colin","orcid":null,"position":9,"is_corresponding":false},{"id":1663872,"name":"Dominique Figarella‐Branger","orcid":null,"position":10,"is_corresponding":false},{"id":1387148,"name":"Céline Chappé","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Dysembryoplastic Neuroepithelial Tumors Share with Pleomorphic Xanthoastrocytomas and Gangliogliomas <scp>BRAF<sup>V600E</sup></scp> Mutation and Expression","abstract":"<jats:title>Abstract</jats:title><jats:p>Pediatric cortical glioneuronal benign tumors mainly include gangliogliomas (<jats:styled-content style=\"fixed-case\">GG</jats:styled-content>) [differential diagnoses pilocytic astrocytomas (<jats:styled-content style=\"fixed-case\">PA</jats:styled-content>) and pleomorphic xanthoastrocytomas (<jats:styled-content style=\"fixed-case\">PXA</jats:styled-content>)] and dysembryoplastic neuroepithelial tumor (<jats:styled-content style=\"fixed-case\">DNT</jats:styled-content>). <jats:styled-content style=\"fixed-case\">DNT</jats:styled-content> include the specific form and the controversial non‐specific form that lack the specific glioneuronal element. Our aims were to search for <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<jats:sup>V600E</jats:sup></jats:styled-content></jats:italic> mutation and <jats:styled-content style=\"fixed-case\">CD</jats:styled-content>34 expression in <jats:styled-content style=\"fixed-case\">DNT</jats:styled-content>, <jats:styled-content style=\"fixed-case\">PXA</jats:styled-content>, <jats:styled-content style=\"fixed-case\">GG</jats:styled-content> and <jats:styled-content style=\"fixed-case\">PA</jats:styled-content> to correlate <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<jats:sup>V600E</jats:sup></jats:styled-content></jats:italic> mutation with <jats:styled-content style=\"fixed-case\">BRAF<jats:sup>V600E</jats:sup></jats:styled-content> expression and to evaluate their diagnostic and prognostic values. Ninety‐six children were included. <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<jats:sup>V600E</jats:sup></jats:styled-content></jats:italic> mutation was studied by sequencing and immunohistochemistry; <jats:styled-content style=\"fixed-case\">CD</jats:styled-content>34 expression was analyzed by immunohistochemistry. <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<jats:sup>V600E</jats:sup></jats:styled-content></jats:italic> mutation was detected in <jats:styled-content style=\"fixed-case\">PXA</jats:styled-content> (60%), <jats:styled-content style=\"fixed-case\">GG</jats:styled-content> (38.7%), <jats:styled-content style=\"fixed-case\">DNT</jats:styled-content> (30%, including 3/11 specific and 3/9 non‐specific forms) and <jats:styled-content style=\"fixed-case\">PA</jats:styled-content> (12.5%). <jats:styled-content style=\"fixed-case\">BRAF<jats:sup>V600E</jats:sup></jats:styled-content> expression was recorded in <jats:styled-content style=\"fixed-case\">PXA</jats:styled-content> (60%), <jats:styled-content style=\"fixed-case\">GG</jats:styled-content> (45.2%) and <jats:styled-content style=\"fixed-case\">DNT</jats:styled-content> (30%). <jats:styled-content style=\"fixed-case\">CD34</jats:styled-content> expression was recorded in <jats:styled-content style=\"fixed-case\">PXA</jats:styled-content> (60%), <jats:styled-content style=\"fixed-case\">GG</jats:styled-content> (58.1%), <jats:styled-content style=\"fixed-case\">DNT</jats:styled-content> (25%) and <jats:styled-content style=\"fixed-case\">PA</jats:styled-content> (12.5%). Neither <jats:styled-content style=\"fixed-case\">CD</jats:styled-content>34 expression nor <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<jats:sup>V600E</jats:sup></jats:styled-content></jats:italic> status was predictive of prognosis, except for <jats:styled-content style=\"fixed-case\">PA</jats:styled-content> tumors where <jats:styled-content style=\"fixed-case\">CD</jats:styled-content>34 expression was associated with a shorter overall survival. In conclusion, <jats:styled-content style=\"fixed-case\">DNT</jats:styled-content> shared with <jats:styled-content style=\"fixed-case\">PXA</jats:styled-content> and <jats:styled-content style=\"fixed-case\">GG</jats:styled-content>, <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<jats:sup>V600E</jats:sup></jats:styled-content></jats:italic> mutation and/or <jats:styled-content style=\"fixed-case\">CD</jats:styled-content>34 expression, which represent molecular markers for these tumors, and we recommend searching for <jats:styled-content style=\"fixed-case\">CD</jats:styled-content>34 expression and <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<jats:sup>V600E</jats:sup></jats:styled-content></jats:italic> mutation in all <jats:styled-content style=\"fixed-case\">DNT</jats:styled-content>, especially the non‐specific forms.</jats:p>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19767382","pmcid":null,"openalex_id":null,"authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"bronze","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bpa.12048","host_type":"publisher"},{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fbpa.12048","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/bpa.12048","host_type":"publisher"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8029244","host_type":"repository"}],"fields_of_study":[],"mesh_terms":[],"keywords":[],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T08:49:11.700114Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}